Package Leaflet: Information for the Patient
Sitagliptin AshCure 25 mg film-coated tablets EFG
Sitagliptin AshCure 50 mg film-coated tablets EFG
Sitagliptin AshCure 100 mg film-coated tablets EFG
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Sitagliptin AshCure contains the active substance sitagliptin, which belongs to a class of medicines called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors) that reduce blood sugar levels in adult patients with type 2 diabetes mellitus.
This medicine helps to increase the amount of insulin produced after a meal and decreases the amount of sugar produced by the body.
Your doctor has prescribed this medicine to help you reduce your blood sugar level, which is too high due to your type 2 diabetes. This medicine can be used alone or in combination with other medicines (insulin, metformin, sulfonylureas, or glitazones) that reduce blood sugar levels, which you may already be taking for your diabetes, along with your diet and exercise program.
What is type 2 diabetes?
Type 2 diabetes is a condition where your body does not produce enough insulin, and the insulin it produces does not work as well as it should. Your body may also produce too much sugar. When this happens, sugar (glucose) builds up in the blood. This can cause serious medical problems, such as heart disease, kidney disease, blindness, and amputation.
Do not take Sitagliptin AshCure
Warnings and precautions
There have been reports of pancreatitis (inflammation of the pancreas) in patients treated with sitagliptin (see section 4).
If you notice blisters on your skin, it may be a sign of a disease called bullous pemphigoid. Your doctor may ask you to stop taking sitagliptin.
Tell your doctor if you have or have had:
It is unlikely that this medicine will cause low blood sugar because it does not work when blood sugar levels are low. However, when this medicine is used in combination with a medicine that contains a sulfonylurea or with insulin, low blood sugar (hypoglycemia) may occur. Your doctor may reduce the dose of your sulfonylurea or insulin medicine.
Children and adolescents
Children and adolescents under 18 years of age should not use this medicine. It is not effective in children and adolescents aged between 10 and 17 years. It is not known if this medicine is safe and effective when used in children under 10 years of age.
Other medicines and Sitagliptin AshCure
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
In particular, tell your doctor if you are taking digoxin (a medicine used to treat irregular heartbeat and other heart problems). Your doctor may need to check your digoxin levels if you are taking sitagliptin.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
This medicine should not be taken during pregnancy.
It is not known if this medicine passes into breast milk. You should not take this medicine if you are breastfeeding or planning to breastfeed.
Driving and using machines
The effect of this medicine on your ability to drive or use machines is negligible. However, dizziness and drowsiness have been reported, which may affect your ability to drive or use machines.
Also, taking this medicine with sulfonylurea or insulin medicines may cause low blood sugar (hypoglycemia), which may affect your ability to drive or use machines or work without a safe support.
Sitagliptin AshCure contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; this is essentially "sodium-free".
Take this medicine exactly as your doctor has told you. If you are not sure, ask your doctor or pharmacist.
The recommended dose is:
If you have kidney problems, your doctor may prescribe a lower dose (such as 25 mg or 50 mg).
You can take this medicine with or without food and drink.
Your doctor may prescribe this medicine alone or with other medicines that also reduce blood sugar levels.
Diet and exercise can help your body use sugar better. It is important that you follow the diet and exercise recommended by your doctor while taking sitagliptin.
If you take more Sitagliptin AshCure than you should
If you take more of this medicine than you should, contact your doctor immediately.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone: 91 562 04 20, indicating the medicine and the amount taken.
If you forget to take Sitagliptin AshCure
If you forget a dose, take it as soon as you remember. If you do not remember until the time of your next dose, skip the missed dose and continue with your regular schedule. Do not take a double dose of this medicine.
If you stop taking Sitagliptin AshCure
Keep taking this medicine while your doctor tells you to, so it can continue to help control your blood sugar levels. You should not stop taking this medicine without first talking to your doctor.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
STOP taking sitagliptin and contact a doctor immediatelyif you notice any of the following serious side effects:
Severe and persistent abdominal pain (in the stomach area) that may radiate to the back
If you have a severe allergic reaction (frequency not known), including skin rash, hives, blisters on the skin/exfoliative skin conditions, and swelling of the face, lips, tongue, and throat that may cause difficulty breathing or swallowing, stop taking this medicine and consult your doctor immediately. Your doctor will prescribe a medicine to treat the allergic reaction and change your diabetes medicine.
Some patients experienced the following side effects after adding sitagliptin to their treatment with metformin:
Common (may affect up to 1 in 10 people): low blood sugar, nausea, flatulence, vomiting.
Uncommon (may affect up to 1 in 100 people): stomach pain, diarrhea, constipation, drowsiness.
Some patients experienced different types of stomach upset when they started taking sitagliptin and metformin together (frequency classified as common).
Some patients experienced the following side effects while taking sitagliptin in combination with a sulfonylurea and metformin:
Very common (may affect more than 1 in 10 people): low blood sugar
Common: constipation.
Some patients experienced the following side effects while taking sitagliptin and pioglitazone:
Common: flatulence, swelling of hands or feet.
Some patients experienced the following side effects while taking sitagliptin in combination with pioglitazone and metformin:
Common: swelling of hands or feet.
Some patients experienced the following side effects while taking sitagliptin in combination with insulin (with or without metformin):
Common: flu.
Uncommon: dry mouth.
Some patients experienced the following side effects while taking sitagliptin alone during clinical trials or after marketing authorization, alone and/or in combination with other diabetes medicines:
Common: low blood sugar, headache, upper respiratory tract infection, nasal congestion or runny nose, and sore throat, arthrosis, pain in the arm or leg
Uncommon: dizziness, constipation, itching.
Rare: reduced platelet count.
Frequency not known: kidney problems (which may require dialysis), vomiting, joint pain, muscle pain, back pain, interstitial lung disease, bullous pemphigoid (a type of skin blister).
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if it is not listed in this leaflet. You can also report side effects directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the label, blister, and carton after "EXP". The expiry date refers to the last day of the month shown.
This medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
Composition of Sitagliptin AshCure
The active substance is sitagliptin:
The other ingredients (excipients) are:
Appearance and packaging
The 25 mg film-coated tablets of Sitagliptin AshCure are round, pink, with the inscription "SH1" engraved on one side and no inscription on the other.
The 50 mg film-coated tablets of Sitagliptin AshCure are round, light beige, with the inscription "SH2" engraved on one side and no inscription on the other.
The 100 mg film-coated tablets of Sitagliptin AshCure are round, beige, with the inscription "SH3" engraved on one side and no inscription on the other.
Sitagliptin AshCure 25 mg, 50 mg, and 100 mg film-coated tablets are available in:
Not all pack sizes may be marketed.
Marketing authorization holder and manufacturer
Marketing authorization holder
AshCure Pharma B.V.
Aristotelesstraat 18,
1064 LD, Amsterdam,
Netherlands.
ManufacturerPharmadox Healthcare Limited
KW20A Kordin Industrial Park,
Paola PLA 3000, Malta
This medicine is authorized in the Member States of the European Economic Area under the following names:
Germany: Sitagliptin AshCure 25 mg film-coated tablets
Sitagliptin AshCure 50 mg film-coated tablets
Sitagliptin AshCure 100 mg film-coated tablets
Spain: Sitagliptina AshCure 25 mg film-coated tablets EFG
Sitagliptina AshCure 50 mg film-coated tablets EFG
Sitagliptina AshCure 100 mg film-coated tablets EFG
Netherlands: Sitagliptine AshCure 25 mg film-coated tablets
Sitagliptine AshCure 50 mg film-coated tablets
Sitagliptine AshCure 100 mg film-coated tablets
Poland: Sitagliptin AshCure 25 mg film-coated tablets
Sitagliptin AshCure 50 mg film-coated tablets
Sitagliptin AshCure 100 mg film-coated tablets
Czech Republic: Sitagliptin AshCure 25 mg film-coated tablets
Sitagliptin AshCure 50 mg film-coated tablets
Sitagliptin AshCure 100 mg film-coated tablets
Portugal: Sitagliptina AshCure 25 mg film-coated tablets
Sitagliptina AshCure 50 mg film-coated tablets
Sitagliptina AshCure 100 mg film-coated tablets
Date of last revision of this leaflet:November 2024
Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/